Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.4100
+0.0050 (1.23%)
At close: Mar 6, 2026
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.69 billion as of March 6, 2026. Its market cap has increased by 41.38% in one year.
Market Cap
1.69B
Enterprise Value
1.92B
Revenue
464.53M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.41
Market Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.69B, a decrease of -66.12%. That is a compound annual growth rate of -14.77%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 1.69B | -18.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Clover Biopharmaceuticals | 2.31B |
| Frontage Holdings | 2.19B |
| Antengene Corporation | 2.15B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.96B |
| Zhaoke Ophthalmology | 1.74B |
| Cutia Therapeutics | 1.60B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.50B |
| Immunotech Biopharm | 1.45B |